Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Patients must be \< 31 years of age at the time of enrollment.

Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) (verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites at the time of diagnosis) and have been designated as having high-risk disease based on Children's Oncology Group (COG) risk classification. The following disease groups are eligible:

* Patients with International Neuroblastoma Risk Group (INRG) Stage M disease with any of the following features:

* MYCN amplification (\> 4-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features; OR

* Age \> 547 days at the time of diagnosis regardless of biologic features; OR

* Age 365-547 days at the time of diagnosis with tumors with unfavorable histology and/or deoxyribonucleic acid (DNA) index = 1

* Patients with INRG Stage MS disease with MYCN amplification

* Patients with INRG Stage L2 disease with either of the following features:

* MYCN amplification (\> 4-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features; OR

* Age \> 547 days at the time of diagnosis with MYCN non-amplified tumors with unfavorable histology

* Note: Patients observed or patients treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet criteria will also be eligible

Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years

Prior therapy

* All patients must have completed high-risk Induction therapy with 4-6 cycles of chemotherapy

* After completion of Induction therapy, patients may have received no more than 4 cycles of bridging chemotherapy or chemo-immunotherapy prior to ASCT

* Patients cannot have previously progressed on immunotherapy with dinutuximab or other anti-GD2 monoclonal antibody

* All patients must have had undergone surgical resection of their primary tumor as part of frontline therapy. Exceptions to this requirement include patients who had a complete response to Induction chemotherapy, patients with no identifiable primary tumor, and patients for whom the institutional surgical team determined that potential risks outweighed potential benefits of resection

* All patients must have undergone tandem high-dose chemotherapy with ASCT as part of Consolidation

* Patients must enroll between day +56 and day +200 from the peripheral blood stem cell (PBSC) infusion following the last dose of high-dose chemotherapy during Consolidation

* All patients must have undergone external beam radiation therapy. Exceptions to this requirement include patients who had no identifiable primary tumor and no persistent metastatic disease at the end of Induction. For patients who received radiotherapy, at least 7 days must have elapsed between completion of radiotherapy and enrollment on this study

Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days of entry on this study. Seven days must have elapsed since administration of a short-acting myeloid growth factor

Peripheral absolute neutrophil count (ANC) \>= 750/uL

Platelet count \>= 50,000/uL (transfusion independent for \>= 7 days)

Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2, or a serum creatinine based on age/gender as follows:

* Age: Maximum Serum Creatinine (mg/dL)

* 6 months to \< 1 year: 0.5 (male and female)

* 1 to \< 2 years: 0.6 (male and female)

* 2 to \< 6 years: 0.8 (male and female)

* 6 to \< 10 years: 1 (male and female)

* 10 to \< 13 years: 1.2 (male and female)

* 13 to \< 16 years: 1.5 (male), 1.4 (female)

* \>= 16 years: 1.7 (male), 1.4 (female)

* Note: Patients with history of transplant associated-thrombotic microangiopathy (TA-TMA) must have a creatinine clearance or radioisotope GFR at baseline to assess renal function and must meet the above criteria

Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age

Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 5.0 x ULN for age (=\< 225 U/L)

* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L

Shortening fraction of \>= 27% by echocardiogram, or ejection fraction of \>= 50% by echocardiogram or radionuclide angiogram

Absence of dyspnea at rest

If pulmonary function tests (PFTs) are performed, forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) must be \> 60%

No clinical evidence of active central nervous system (CNS) disease at the time of study enrollment

Patients with seizure disorder may be enrolled if on non-enzyme-inducing anticonvulsants and well controlled

CNS toxicity from prior therapy =\< grade 2

What this study is about